Brain tumors are amongst the deadliest of all cancer subtypes.  Despite vast advancements in our understanding of the basic biology of brain tumors, there has been little improvement in patient outcomes.  Glioblastoma (GBM), the most common primary brain tumor, remains an essentially incurable disease.  Despite multimodality treatment with surgery, chemotherapy and radiotherapy, median survival is only 12-15 months.  There is a vast unmet need for improved therapies for GBM, but also many impediments to neuro�oncology drug development. For example, emerging evidence suggests that the subpopulation of cancer initiating cells is intrinsically chemo- and radio-resistant.  Moreover, the blood-brain-barrier is an impediment to therapeutic drug delivery.  This presentation will review some of the pre-clinical and clinical considerations for novel therapeutic development for brain tumors.  I will discuss studies focused on increasing GBM apoptosis with the goal of overcoming resistance to therapy. I will also discuss an emerging strategy of inhibiting nuclear export.

Clinical and preclinical considerations for neuro-oncology drug development

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.